Fengying Y. Wu - Publications

Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: June 16, 2026

Radiological pure-solid appearance clinical stage I lung adenocarcinoma: a comparative study of mucinous and non-mucinous adenocarcinoma based on imaging features and survival outcomes.

Journal: Insights into imaging

Published: January 08, 2026

Primary pulmonary enteric adenocarcinoma: A single-institute retrospective study on its imaging classification and survival outcomes.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: November 12, 2025

Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial.

Journal: Chinese medical journal

Published: August 12, 2025

GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: June 19, 2025

Ablation plus immunotherapy versus immunotherapy alone in patients of advanced NSCLC who develop oligo-residual disease after anti-PD-1/L1 therapy (BOOSTER): a randomized phase 2 trial.

Journal: Signal transduction and targeted therapy

Published: April 03, 2025

WISP3 upregulates SDCBP expression to promote the progression of non-small cell lung cancer via the TGF-β signaling pathway.

Journal: Biochemical pharmacology

Published: March 27, 2025

IFITM3 enhances immunosensitivity via MHC-I regulation and is associated with the efficacy of anti-PD-1/-L1 therapy in SCLC.

Journal: Molecular cancer

Published: March 13, 2025

Corrigendum To: PIWIL1 Promotes Malignant Progression of Papillary Thyroid Carcinoma by Inducing EVA1A Expression.

Journal: Current cancer drug targets

Published: February 25, 2025

BIRC5 expression correlates with immunosuppressive phenotype and predicts inferior response to immunotherapy in lung adenocarcinoma.

Journal: Journal of thoracic disease

Published: February 03, 2025

Delineating unique MASH-endothelial cells in metabolic dysfunction-associated steatotic liver disease using single-cell lensing.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: January 17, 2025

Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.

Journal: Journal for immunotherapy of cancer

Published: October 10, 2024